中信证券股份有限公司 关于广东丸美生物技术股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"）作为广东丸美生物技术股 份有限公司（以下简称"丸美生物"或"公司"）首次公开发行股票的保荐人， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》 《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，对丸美生物使用部分闲置募集资金进行现金管理事项进行了审 慎核查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》 （证监许可[2019]917 号）核准，并经上海证券交易所同意， 丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为每股 人民币 20.54 元。共计募集资金人民币 84,214.00 万元，扣除各项发行费用人民 币 5,213.80 万元后的募集资金净额为人民币 79,000.20 万元。上述募集资金到位 情 ...

Core Viewpoint - The company plans to use up to RMB 200 million of idle raised funds for cash management to improve fund utilization efficiency while ensuring that it does not affect the normal operation of fundraising projects [1][4][6]. Fundraising Basic Situation - The company raised a total of RMB 842.14 million from its initial public offering, with a net amount of RMB 790 million after deducting issuance costs of RMB 52.14 million [1]. - As of June 30, 2025, the company has used RMB 535.18 million of the raised funds, leaving a balance of RMB 254.82 million [2]. Fund Management and Usage - The company has signed agreements with banks for the management of raised funds, ensuring that funds are stored in dedicated accounts under strict supervision [2]. - The company has invested in various projects, including a cosmetics smart manufacturing factory and marketing upgrades, with total investments amounting to RMB 932.65 million [3]. Cash Management Plan - The company intends to invest the idle funds in low-risk, principal-protected financial products, excluding securities investments [4][5]. - The cash management plan is valid for twelve months from the board meeting date and allows for rolling use of the RMB 200 million limit [1][6]. Impact on Daily Operations - The cash management initiative is designed to enhance fund efficiency without affecting the normal operations of fundraising projects or the company's main business [6][8]. - The decision-making process for this cash management plan has been deemed legal and compliant with relevant regulations [7][9].

Group 1 - The company reported its main operational data for Q2 2025, including production, sales, and revenue figures for its key products [1][2] - The total production and sales figures for the main product categories are as follows: Eye products (1,417,633 produced, 1,293,001 sold, revenue of 206,219,439 yuan), Skincare products (4,321,217 produced, 4,012,166 sold, revenue of 364,708,224 yuan), Cleansing products (1,248,862 produced, 1,089,700 sold, revenue of 65,706,024 yuan), and Beauty products (2,942,370 produced, 3,173,964 sold, revenue of 268,017,038 yuan) [1] - The average selling price of eye products increased by 57.93% to 159.49 yuan due to a higher proportion of upgraded eye cream sales and a lower proportion of eye mask sales [1][2] Group 2 - The average selling price of beauty products increased by 42.78% to 84.44 yuan, attributed to optimized marketing strategies that reduced low-priced promotional items [2] - The company experienced a decrease in the prices of key raw materials, including propylene glycol and butylene glycol, which helped lower procurement costs by 2% [2] - The company implemented large-scale procurement strategies, resulting in a 10% decrease in packaging materials, a 15% decrease in tube packaging, and a 24% decrease in certain box packaging materials [2]

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the management of raised funds by Guangdong Marubi Biotechnology Co., Ltd. for the first half of 2025, highlighting the total amount raised, its usage, and the management practices in place to ensure compliance with regulations. Group 1: Fundraising Overview - The company raised a total of RMB 842,140,000.00 from the issuance of 41 million shares at RMB 20.54 per share, with net proceeds amounting to RMB 790,001,978.42 after deducting issuance costs of RMB 52,138,021.58 [1] - As of June 30, 2025, the total amount used from the raised funds was RMB 535,181,303.64, with a remaining balance of RMB 270,426,824.67 in the dedicated fundraising account [1][2] Group 2: Fund Management Practices - The company has established a dedicated fund management system in compliance with relevant regulations, including the opening of special accounts for fundraising and signing of tripartite supervision agreements with sponsors and banks [1] - The remaining balance in the fundraising account as of June 30, 2025, is distributed across various banks, with RMB 236,579,195.01 held in one account and RMB 25,918,241.87 in another [1] Group 3: Fund Usage and Projects - The company has not used idle funds for temporary working capital or to repay bank loans, nor has it changed the use of raised funds for ongoing or new projects [2][3] - The construction of the "Cosmetics Intelligent Manufacturing Factory" has been completed, but production line construction is still pending, with plans for future capacity and project arrangements based on market conditions [2][3] Group 4: Compliance and Reporting - The company has adhered to the fundraising management regulations and has not encountered any significant violations in the use of raised funds [2] - There are no changes in the implementation location or method of the fundraising projects, and no early investments or replacements have occurred [3]

广东丸美生物技术股份有限公司2025 年半年度报告 公司代码：603983 公司简称：丸美生物 广东丸美生物技术股份有限公司 广东丸美生物技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人孙怀庆、主管会计工作负责人王开慧及会计机构负责人（会计主管人员）黄丹 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 以实施权益分派股权登记日登记的总股本为基数，向实施权益分派股权登记日登记在册的全 体股东每10股派发现金红利2.50元（含税）。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是 ...

| 持股比 | | 持股 | | 持有有限 | | | 质押、标记或冻结 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 股东性质 | | | | | 售条件的 | | | | | 例(%) | | 数量 | | | | 的股份数量 | | | | | | | | 股份数量 | | | | | | 孙怀庆 境外自然人 | | 72.72 | 291,600,000 | | 0 | 无 | 0 | | | 王晓蒲 境外自然人 | | 8.08 | 32,400,000 | | 0 | 无 | 0 | | | 凯石基金－展麟价值精选 | | | | | | | | | | 未知 | 2.74 | 10,976,601 | | 0 | 未知 | 未知 | | | | 凯石基金飞跃二号单一资 | | | | | | | | | | 产管理计划 | | | | | | | | | | 香港中央结算有限公司 | 未知 | 1.21 | | 4,850,028 | | 0 | 未知 | 未知 | | 交通银行股份有限公司－ | | | | ...

广东丸美生物技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：603983 证券简称：丸美生物 公告编号：2025-023 二、公司履行的决策程序 （一）董事会会议的召开、审议和表决情况 公司于 2025 年 8 月 21 日召开第五届董事会第七次会议，审议并通过了 2025 年半年度利润分配方案，方案符合公司章程规定的利润分配政策和公司股东回报 规划。 上述事项尚需提交公司 2025 年第一次临时股东大会审议。 （二）监事会意见 重要内容提示： ? 利润分配比例：每10股派发现金红利2.50元（含税）。 ? 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生 变动的，拟维持每股分配比例不变，相应调整每股分配总额，并将在相关公告中 披露。 为积极合理回报投资者、共享企业价值，增强投资者获得感，广东丸美生物 技术股份有限公司（本文简称"公司"）结合经营发展实际情况以及对未来发展 的信心，综合考虑股东利益，制定了2 ...

Meeting Overview - The fifth meeting of the board of directors of Guangdong Marubi Biotechnology Co., Ltd. was held on August 21, 2025, with all 9 directors present [1] - The meeting was convened in compliance with relevant laws and regulations, and the resolutions passed are legally valid [1] Resolutions Passed - All resolutions were approved with 9 votes in favor, 0 against, and 0 abstentions [2][3] - The resolutions included the approval of the 2025 semi-annual report and the special report on the use of raised funds [2] Financial Decisions - The company and its subsidiaries are authorized to apply for a comprehensive credit limit of up to 1.2 billion RMB for various financing activities [3] - A cash dividend of 2.50 RMB (including tax) per 10 shares will be distributed to shareholders based on the total share capital on the record date [3] Upcoming Events - The company will hold its first extraordinary general meeting of 2025 to review the proposed resolutions [4]

公司 2025 年半年度报告及其摘要的编制和审议程序、内容、格式符合中国 证监会和上海证券交易所的有关规定；报告内容真实、客观地反映公司的财务状 况和经营成果；在提出本意见前，未发现参与 2025 年半年度报告编制和审议的 人员有违反保密规定及其他违反法律法规、 《公司章程》或损害公司利益的行为。 证券代码：603983 证券简称：丸美生物 公告编号：2025-019 广东丸美生物技术股份有限公司 关于第五届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 广东丸美生物技术股份有限公司（以下简称"公司"）第五届监事会第六次 会议于 2025 年 8 月 21 日（星期四）在公司会议室以现场结合通讯方式召开。会 议通知已于 2025 年 8 月 11 日以电子邮件、微信方式发出。本次会议应出席监事 律、法规、部门规章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 表决情况：3 票同意，0 票反对，0 票弃权。 公司《2025 年半年度募集资金存放与使用情况的专项报 ...

丸美生物8月22日披露半年报，公司上半年实现营业收入17.69亿元，同比增长30.83%；归属于上市公司 股东的净利润1.86亿元，同比增长5.21%；基本每股收益0.46元。公司拟向全体股东每10股派发现金红 利2.5元（含税）。 ...